Form 4: Aldeyra Therapeutics Director Gary Phillips Granted Over 71,000 Stock Options

Aldeyra Therapeutics, Inc. Director Gary M. Phillips was granted 71,172 stock options with an exercise price of $2.685, vesting over one year subject to continued service.

Summary

• Aldeyra Therapeutics, Inc. Director Gary M. Phillips was granted a total of 71,172 stock options on June 10, 2025.
• The options have an exercise price of $2.685 per share and an expiration date of June 9, 2035.
• A grant of 62,728 options vests 100% on the one-year anniversary of the grant date, contingent on Mr. Phillips' continuous service as a member of the Board of Directors.
• An additional 4,825 options vest 100% on the one-year anniversary of the grant date, contingent on continuous service as a member of the Compensation Committee of the Board.
• A further 3,619 options vest 100% on the one-year anniversary of the grant date, contingent on continuous service as a member of the Audit Committee of the Board.

Sentiment

Score: 7

Explanation: The document reports a routine equity compensation grant to a director, which is a positive for aligning management interests with shareholders and is a standard corporate governance practice. It does not contain any negative financial or operational news.

Positives

• The grant of stock options aligns the interests of Director Gary M. Phillips with those of the shareholders, as the value of the options increases with the company's stock price.
• Equity compensation is a standard practice for retaining and incentivizing experienced board members.

Risks

• The vesting of the stock options is contingent upon Gary M. Phillips providing continuous service as a member of the Board of Directors, Compensation Committee, and Audit Committee through the applicable vesting dates. Failure to meet these service conditions would result in forfeiture of unvested options.

Future Outlook

The grant of these stock options, with their one-year vesting period, indicates an expectation of continued service from Director Gary M. Phillips, aligning his future incentives with the company's performance.

Industry Context

The granting of stock options to directors is a common form of compensation in the biotechnology and pharmaceutical industries, aiming to attract and retain experienced leadership and align their long-term interests with company performance and shareholder value.

Comparison to Industry Standards

• The structure of this equity grant, including the one-year cliff vesting tied to continuous service, is a standard practice for director compensation across many publicly traded companies, including those in the biotech sector.
• The exercise price being set at the market price on the grant date (assuming $2.685 was the market price) is typical for incentive stock options.

Corporate Governance

Related Party Transactions

• The grant of stock options to Gary M. Phillips, a director of Aldeyra Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided to an insider.

Stakeholder Impact

• Shareholders: The grant aligns the director's incentives with shareholder interests, potentially leading to better long-term performance. However, it also represents potential future dilution if options are exercised.
• Employees: While not directly impacting all employees, such compensation practices can set a precedent for executive and director incentives within the company.

Next Steps

• The stock options will become exercisable on the one-year anniversary of the grant date (June 10, 2026), provided the vesting conditions related to continuous service are met.

Key Dates

Recommendation

Keywords

Aldeyra Therapeutics, ALDX, Stock Options, Form 4, Director Compensation, Equity Grant, Insider Transaction, Corporate Governance, Biotechnology